Quality Investor

OptimizeRx Corporation

Rank #108Op. LeverageWatchlistCompare with other stocks

OPRX · Nasdaq · Healthcare

OptimizeRx Corporation (OPRX) — Rank #108 by gross profitability (GP/assets 0.45) · ROE 3.9% · Piotroski F-Score 8 / 9.

As-of 2026-10-30 · CIK 0001448431 · all metrics point-in-time as of the filing date.

About

OptimizeRx Corporation operates as a digital healthcare technology company.

Show more

It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms.

The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Industry
Health Information Services
Sector
Healthcare
State
NV
Filer Category
Non-accelerated filerSmaller reporting company
Fiscal Year End
December 31

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

132

Industry

Health Information Services

Exchange

Nasdaq

11/12

Flags passed

OPRX passes 11/12 quality flags

1 caution to review

  • CAUTION
    Dilution above 2%

    Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation

  • PASS
    Gross margin holding
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Deferred revenue growing

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.45
Return on equity
3.9%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.25
Current ratio
5.58×
Net cash
$5.09M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
6.4%

Growth

1/2 pass
Revenue growth
18.8%
Piotroski F-Score
8 / 9
Share dilution
3.9%

Operating margin expansion and free cash flow are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 0.45

Gross profitability (GP / assets)

0.45

Primary signal (Novy-Marx).

4th of 11 SIC 7389 peers

Return on equity

3.9%

Gross margin

67.3%

3rd of 11 SIC 7389 peers

Revenue growth (YoY)

18.8%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

20.6%

Revenue CAGR (5Y)

20.4%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

20.8%

Cash Flow Health

Is the cash real?

No warning flags · FCF 264% above net income

Free cash flow

$18.66M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

263.5%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

6.4%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

Caution: Dilution above 2% · net cash $5.09M, F-Score 8/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.25

1st of 10 SIC 7389 peers (best = lowest)

Current ratio

5.58×

1st of 11 SIC 7389 peers

Quick ratio

5.03×

Net cash

$5.09M

Cash & equivalents minus total debt.

Piotroski F-Score

8 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

1.3 / 5

Weak
Share count trend
3.9%1/5 Weak
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory
-22.2%0/5 Weak

Lifecycle Phase History

20202025
Hypergrowth
Startup
Op. Leverage

Price History

OPRX-88.9% · -35.5% CAGRSPY+82.9% · +12.8% CAGR